Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T17:36:44.189Z.
Calculation as of: 2026-10-06T17:36:44.189Z.
Quote observation: 2026-10-06T17:27:31.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 76b79f67d555c15c1d19b9a53ec9076b1294dcb64452140a50102a9ec63499e7
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$8.33M
Price/FCF Ratio
N/A
TTM Avg
9.96
3Y Avg
9.96
5Y Avg
9.96
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | $7.95M | N/A | N/A | N/A | N/A |
| Traws Pharma, Inc. (TRAW)vs › | $7.96M | N/A | N/A | N/A | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $8.01M | N/A | N/A | N/A | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $8.01M | N/A | N/A | N/A | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.81M | N/A | N/A | N/A | N/A |
| HeartSciences Inc. (HSCS)vs › | $8.20M | N/A | N/A | N/A | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.33M | N/A | 9.96 | 9.96 | 9.96 |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.73M | N/A | N/A | N/A | N/A |
| DataMEDS AI, Inc. (MEDS)vs › | $8.53M | N/A | N/A | N/A | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.27M | N/A | 41006.18 | 41006.18 | 41006.18 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
